Link between type 2 diabetes mellitus and hepatocellular carcinoma

doi:10.4254/wjh.v17.i7.107675

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series.

Item

Count

PDF

HTML

Figures (1-2)

Sum=0

Jul 27, 2025 (publication date) through Jul 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Jul 27, 2025; 17(7): 107675
Published online Jul 27, 2025. doi: 10.4254/wjh.v17.i7.107675

Link between type 2 diabetes mellitus and hepatocellular carcinoma

Somdatta Giri, Alpana Mukhuty, Samim A Mondal, Jayaprakash Sahoo, Ayan Roy, Sadishkumar Kamalanathan, Dukhabandhu Naik

Somdatta Giri, Ayan Roy, Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, Kayani 741245, West Bengal, India

Alpana Mukhuty, Department of Zoology, Rampurhat College, Birbhum 731224, West Bengal, India

Samim A Mondal, Jayaprakash Sahoo, Sadishkumar Kamalanathan, Dukhabandhu Naik, Department of Endocrinology and Metabolism, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry 605006, India

Co-first authors: Somdatta Giri and Alpana Mukhuty.

Author contributions: Giri S did the literature search wrote the first draft and gave intellectual input; Giri S and Mukhuty A contributed equally to this article, they are the co-first authors of this manuscript; Mondal SA and Mukhuty A did the mechanistic approach; Sahoo J, Roy A, Kamalanathan S, and Naik D conceptualized the work, supervised the writing, gave intellectual inputs, and critically revised the manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Jayaprakash Sahoo, DM, Full Professor, Department of Endocrinology and Metabolism, Jawaharlal Institute of Postgraduate Medical Education and Research, D. Nagar, Gorimedu, JIPMER Campus, Puducherry 605006, India. jppgi@yahoo.com

Received: April 7, 2025
Revised: April 29, 2025
Accepted: July 2, 2025
Published online: July 27, 2025
Processing time: 119 Days and 20.2 Hours

Core Tip

Core Tip: Type 2 diabetes mellitus increases the hepatocellular carcinoma (HCC) risk and also impacts the treatment response of HCC. The molecular pathways of diabetes, development of its complications are interconnected with HCC. However, only a subset of HCC cases in type 2 diabetes mellitus are driven by nonalcoholic fatty liver disease, suggesting the involvement of additional pathogenic pathways. Newer generation anti-diabetic and anti-obesity drugs like sodium-glucose cotransporter-2 inhibitors and incretin analogues can hold promises in the future.